UniQure advances AMT-130 toward BLA with 2026 topline data and strong runway
Jul 29, 2026, 7:08 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Key near-term catalysts include BLA timing (Q3 2026) and September topline data for AMT-130, plus ongoing regulatory progress in the UK; strong cash runway reduces dilution risk and supports execution risk, supporting upside.
AI summary
What happened, with direct paths to the underlying reporting
uniQure disclosed progress on AMT-130, targeting a BLA submission in Q3 2026 with UK MHRA alignment and September four-year topline data. AMT-260 showed encouraging early signals and a solid safety profile. A $259 million follow-on offering extended cash runway into 2030, supporting anticipated commercial launch activities and pipeline investments.
AMT-130 BLA submission planned in Q3 2026 after FDA Type B alignment.
Topline four-year AMT-130 data expected September 2026.
AMT-260 Phase I/IIa shows early seizure reductions and favorable safety.
June 2026 follow-on offering raises $259M, extending runway to 2030.
Cash and investments: $810.3M as of 6/30/2026; funds support into 2030.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
UniQure reported that its Huntington's disease program achieved 44% slowing of disease progression in an ongoing early-to-mid-stage trial but did not meet statistical significance…
UniQure filed for U.S. approval of its Huntington's disease gene therapy after the FDA reversed its prior stance, marking a pivotal regulatory turn. The development drove a ~5% pr…
UniQure reported that the FDA agrees data from a mid-stage study could support an accelerated approval filing for its Huntington's disease gene therapy. This regulatory signal cou…